Novo Nordisk A/S (ETR:NOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 226.80B |
| Revenue (ttm) | 42.26B |
| Net Income (ttm) | 13.89B |
| Shares Out | n/a |
| EPS (ttm) | 3.12 |
| PE Ratio | 16.32 |
| Forward PE | 16.07 |
| Dividend | 1.56 (3.08%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 771,950 |
| Average Volume | 480,794 |
| Open | 51.34 |
| Previous Close | 50.72 |
| Day's Range | 50.90 - 51.56 |
| 52-Week Range | 35.76 - 90.46 |
| Beta | 0.36 |
| RSI | 76.26 |
| Earnings Date | Feb 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections...
NEW: Wegovy launches first-ever once-daily weight loss pill
Novo Nordisk executive vice president of U.S. operations Dave Moore discusses the drugmaker's newly launched once-daily oral weight-loss pill on ‘The Claman Countdown.'
Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham
Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.
Healthy Returns: What to expect from pharma at the JPM conference
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight-loss pill
Amazon said it now offers Novo Nordisk's Wegovy weight-loss pill through its digital pharmacy service. Novo Nordisk began rolling out its first-ever GLP-1 pill in the U.S. earlier this week.
Amazon Pharmacy offers Novo Nordisk's Wegovy pill
Amazon Pharmacy said on Friday it now offers Novo Nordisk's Wegovy pill through insurance plans as well as through a cash-pay option.
Novo Nordisk: A Pill For Growth
Novo Nordisk is rated Buy, with the FDA-approved Wegovy pill seen as a potential catalyst to reignite growth and recapture market share. NVO faces headwinds from lower pill pricing, potential cannibal...
Novo Nordisk: My Top Pick For 2026
Novo Nordisk is my top opportunity for 2026, driven by multiple catalysts and a compelling valuation. The Wegovy pill's FDA approval, aggressive pricing, and first-mover advantage position NVO to rega...
3 of the Best Stocks Under $100 to Buy in 2026
These stocks all pay more than 3% in dividends. They have modest valuations that look dirt cheap when compared to the S&P 500.
Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial?
Novo Nordisk has released a pill version of its GLP-1 drug. In 2025, the company announced that it was ending a GLP-1 trial related to the drug's impact on Alzheimer's.
Novo Nordisk: NVO Stock To $100?
Novo Nordisk's (NYSE: NVO) Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x story moving forward, provided it effectively...
Final Trade: NVO, JPM, COST, MPC
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
Novo Nordisk A/S (NYSE: NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025.
China Market Unsettled, But Novo Nordisk's Oral Wegovy May Keep Revenue On Track
Novo Nordisk A/S launches oral Wegovy in the U.S. at aggressive introductory pricing, aiming to secure early market share and first-mover advantage. NVO faces imminent semaglutide patent expiry in Chi...
Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.
Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
Exclusive: Novo Nordisk's US public affairs head leaves company
Danish obesity drugmaker Novo Nordisk's head of public affairs in the U.S. has left the company, according to an internal memo seen by Reuters, at a time when the firm is battling to revive its fortun...
Novo Nordisk Launches Wegovy™ Pill, Expanding Patient Choice and Access With knownwell as a Recognized NovoCare® Provider
BOSTON--(BUSINESS WIRE)--Novo Nordisk today announced the U.S. launch of the Wegovy™ pill, the first oral GLP-1 option approved by the Food and Drug Administration for chronic weight management. The i...
Novo Nordisk's Wegovy Pill Now Broadly Available Across U.S.
Novo Nordisk's Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said.
UK's pharma regulator could issue a decision for Novo's Wegovy pill by year-end
Britain's medicines regulator said on Monday it was reviewing Novo Nordisk's application for an oral 25 milligram version of its weight-loss drug Wegovy and anticipated making a decision before the en...
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S. The cash prices of the drug, called the Wegovy pi...
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial1 Starting dose of ...
Novo Nordisk to sell Wegovy pill to US self-pay patients starting at $149 per month
Denmark's Novo Nordisk will offer its 1.5 and 4 milligram Wegovy weightloss pills at $149 per month to self-paying patients in the United States from January 5, it said on Monday.
2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026
Its newly earned indications could impact financial results in 2026. The drugmaker should also make decent pipeline progress.
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win' battle in the U.S. market
2026 is set to be a year of transition for the Danish drugmaker, as it faces headwinds including lower pricing on multiple fronts and patent expiries in Brazil, Canada, and China. It follows a difficu...
Novo Nordisk A/S: China's Supreme People's Court delivers a positive ruling on the semaglutide compound patent
Today, the Supreme People's Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent